** Shares of Soleno Therapeutics SLNO.O rise 33.98% to $65.61 premarket

** Late on Wednesday, U.S. FDA approved co's drug to treat a rare genetic disorder, making it first treatment available for patients who experience feelings of intense and persistent hunger

** The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder that is caused by an error in one or more genes

** The drug will have an annual average cost of $466,200 and will be dosed as per patients' weight and will be available from April

** Up to last close, stock up ~9% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))